Clinical Infectious Diseases · 2010 · 166 citations · 13 references
MedicineInfectious DiseasesMaternal HealthHelminthologyMaternal MortalityMaternal-fetal MedicineMaternal ComplicationsMaternal Disease PreventionMaternal Health PreventionMaternal Medical Complications In PregnancyPerinatal Infection PreventionPregnancyInfection Prevention In PregnancyInfections In PregnancyLow Birth Weight ManagementMaternal Adverse EffectsMaternal Anemia PreventionMaternal-fetal Infection PreventionPerinatal ComplicationsPerinatal Mortality Prevention
BACKGROUND: Helminth infections during pregnancy may be associated with adverse outcomes, including maternal anemia, low birth weight, and perinatal mortality. Deworming during pregnancy has therefore been strongly advocated, but its benefits have not been rigorously evaluated. METHODS: In Entebbe, Uganda, 2507 pregnant women were recruited to a randomized, double-blind, placebo-controlled trial investigating albendazole and praziquantel in a 2 x 2 factorial design [ISRCTN32849447]. Hematinics and sulphadoxine-pyrimethamine for presumptive treatment of malaria were provided routinely. Maternal and perinatal outcomes were recorded. Analyses were by intention to treat. RESULTS: At enrollment, 68% of women had helminths, 45% had hookworm, 18% had Schistosoma mansoni infection; 40% were anemic (hemoglobin level, <11.2 g/dL). At delivery, 35% were anaemic; there was no overall effect of albendazole (odds ratio [OR], 0.95; 95% confidence interval [CI], 0.79-1.15) or praziquantel (OR, 1.00; 95% CI, 0.83-1.21) on maternal anemia, but there was a suggestion of benefit of albendazole among women with moderate to heavy hookworm (OR, 0.45; 95% CI, 0.21-0.98; P=.15 for interaction). There was no effect of either anthelminthic treatment on mean birth weight (difference in mean associated with albendazole: -0.00 kg; 95% CI, -0.05 to 0.04 kg; difference in mean associated with praziquantel: -0.01 kg; 95% CI, -0.05 to 0.04 kg) or on proportion of low birth weight. Anthelminthic use during pregnancy showed no effect on perinatal mortality or congenital anomalies. CONCLUSIONS: In our study area, where helminth prevalence was high but infection intensity was low, there was no overall effect of anthelminthic use during pregnancy on maternal anemia, birth weight, perinatal mortality, or congenital anomalies. The possible benefit of albendazole against anemia in pregnant women with heavy hookworm infection warrants further investigation.
13
Mode of action of benzimidazoles
Ernest Lacey · Parasitology Today · 1990 · 587 citations
Effect of mebendazole therapy during pregnancy on birth outcome
NR de Silva, J Sirisena, DPS Gunasekera et al. · The Lancet · 1999 · 153 citations
Medicine, Obstetrics, Pharmacology +12
Use of antenatal services and delivery care in Entebbe, Uganda: a community survey
Moses Kizza, Linda Morison, David Mabey et al. · BMC Pregnancy and Childbirth · 2007 · 142 citations · Full text